Loading...
XNASVYGR
Market cap313mUSD
Jan 08, Last price  
5.73USD
1D
-3.21%
1Q
-16.59%
Jan 2017
-55.02%
IPO
-67.26%
Name

Voyager Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:VYGR chart
P/E
2.37
P/S
1.25
EPS
2.42
Div Yield, %
0.00%
Shrs. gr., 5y
6.81%
Rev. gr., 5y
101.01%
Revenues
250m
+511.16%
0017,334,00014,220,00010,135,0007,619,000104,391,000171,128,00037,415,00040,907,000250,008,000
Net income
132m
P
-7,666,000-16,317,000-29,672,000-40,193,000-70,698,000-88,288,000-40,832,00036,741,000-66,032,000-46,408,000132,330,000
CFO
78m
P
-5,450,000-11,918,00041,299,000-42,482,000-61,350,000-15,887,00048,666,000-96,716,000-53,525,000-12,509,00077,919,000
Earnings
Feb 26, 2025

Profile

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
URL
https://www.voyagertherapeutics.com/
IPO date
Nov 11, 2015
Employees
125
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
250,008
511.16%
40,907
9.33%
Cost of revenue
132,435
97,935
Unusual Expense (Income)
NOPBT
117,573
(57,028)
NOPBT Margin
47.03%
Operating Taxes
1,408
16
Tax Rate
1.20%
NOPAT
116,165
(57,044)
Net income
132,330
-385.14%
(46,408)
-29.72%
Dividends
Dividend yield
Proceeds from repurchase of equity
31,121
1,591
BB yield
-8.27%
-0.68%
Debt
Debt current
3,200
2,832
Long-term debt
37,386
43,420
Deferred revenue
32,359
6,450
Other long-term liabilities
1,001
1,001
Net debt
(191,882)
(74,111)
Cash flow
Cash from operating activities
77,919
(12,509)
CAPEX
(3,256)
(2,491)
Cash from investing activities
(141,643)
(7,339)
Cash from financing activities
33,645
1,110
FCF
92,002
(35,008)
Balance
Cash
230,875
118,848
Long term investments
1,593
1,515
Excess cash
219,968
118,318
Stockholders' equity
(261,186)
(393,693)
Invested Capital
551,159
483,290
ROIC
22.46%
ROCE
40.55%
EV
Common stock shares outstanding
44,569
38,357
Price
8.44
38.36%
6.10
125.09%
Market cap
376,165
60.77%
233,977
129.20%
EV
184,283
159,866
EBITDA
122,014
(50,837)
EV/EBITDA
1.51
Interest
1,792
Interest/NOPBT